PTGS2 and Alzheimer disease: Their targets were acetylcholinesterase (AChE), prostaglandin-endoperoxide synthase 2 (PTGS2), peroxisome proliferator activated receptor γ (PPARγ), IL-1β, glycogen synthase kinase 3 beta (GSK3B), etc. However, these active compounds were docked with AChE, a target which is less likely to be responsible for cognitive deficits as observed in clinical studies, which show Aricept had limited effect on AD (Birks and Harvey, 2018).